Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis.
Laura M SpringGeoffrey FellAndrea ArfeChandni SharmaRachel GreenupKerry L ReynoldsBarbara L SmithBrian M AlexanderBeverly MoySteven J IsakoffGiovanni ParmigianiLorenzo TrippaAditya BardiaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Achieving pCR following NAT is associated with significantly better EFS and OS, particularly for triple-negative and HER2+ breast cancer. The similar outcomes with or without adjuvant chemotherapy in patients who attain pCR likely reflects tumor biology and systemic clearance of micrometastatic disease, highlighting the potential of escalation/deescalation strategies in the adjuvant setting based on neoadjuvant response.See related commentary by Esserman, p. 2771.